↓ Skip to main content
What is this page? Embed badge

Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma

Overview of attention for article published in BMC Health Services Research, November 2022
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (79th percentile)
  • High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

news
1 news outlet

Citations

dimensions_citation
6 Dimensions

Readers on

mendeley
3 Mendeley
Summary News Dimensions citations
So far, Altmetric has seen 1 news story.

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.

This page is provided by Altmetric.